Parkinson Disease
Conditions
Keywords
Parkinson Disease, inspiratory muscle training, oxygen consumption, physical activity
Brief summary
Parkinson's patients usually have a significant decrease in respiratory muscle strength and respiratory function, which may increase in proportion to the severity of the disease. In addition, peripheral muscles may become dysfunctional by the rigidity caused by the disease. This reduces exercise capacity and may lead to a decrease in oxygen consumption. Respiratory muscle training has increased respiratory muscle strength in people with Parkinson's Disease (PD). However, its effectiveness on other functional outcomes has not been determined and studied.
Detailed description
Parkinson's disease is the second most common neurodegenerative disease. The main motor symptoms seen in Parkinson's disease are tremors, rigidity, bradykinesia, and decreased postural reflexes. In addition, respiratory problems that lead to death may often be seen. This is caused by dysfunction in the respiratory muscles and postural abnormalities, as well as changes in upper airway muscle activation and coordination. The coughing or exhaling reflex requires coordinated motor activity, and inadequate airway defence puts patients at risk for pneumonia. Aspiration into the lower airways results in a distinct series of events, including coughing and swallowing as the first attempt to clear the airway. Aspiration pneumonia is seen in Parkinson's patients because the coordination of these processes is unsuccessful, and the cough force is insufficient. Upper airway obstruction may occur due to stiffness and fatigue in the thyroarytenoid muscles. In addition, pathological processes such as bradykinesia, coordination disorder, and inspiratory muscle weakness can cause kyphoscoliosis and a decrease in lung volumes, resulting in restrictive respiratory function abnormality due to decreased chest wall compliance due to rigidity. In Parkinson's disease, respiratory muscles, like other skeletal muscles, are affected by stiffness, and weakness of the respiratory muscles makes it difficult to overcome this stiffness, resulting in reduced lung volumes. It is thought that this condition may develop due to the decrease in elastic retraction of the chest wall. In addition, mitochondrial dysfunction due to the pathogenesis of the disease also leads to deterioration in muscle oxygen metabolism. In individuals with reduced muscle oxygen, exercise tolerance and muscle strength decrease. Autonomic dysfunction of varying severity is observed in almost all patients, depending on the degeneration of spinal autonomic neurons or the side effects of dopaminergic that are part of pharmacological treatment. Patients may experience increased fatigue as well as autonomic dysfunction. Inadequate oxygen delivery and utilization to the muscles may limit skeletal muscle oxygenation and lead to increased use of anaerobic systems, resulting in fatigue. This causes a decrease in the level of physical activity and reduces the quality of life. However, studies investigating the effects of inspiratory muscle training in Parkinson's patients are insufficient. The aim of this study is to investigate the effects of inspiratory muscle training on maximum and functional exercise capacity, muscle oxygen, peripheral and respiratory muscle strength, respiratory muscle endurance, respiratory function, dyspnea, fatigue, cough strength, autonomic dysfunction, physical activity level and quality of life in patients with Parkinson's disease.For this purpose, our study was planned as a randomized, controlled, three-blind (investigators, patient, and analyzer) prospective study. According to the block randomization result, at least 20 patients with a diagnosis of Parkinson's Disease will be included in the training and control groups. Patients in the inspiratory muscle training group will be given inspiratory muscle strength training with the Powerbreathe device at 50% of the maximal inspiratory pressure for a total of 8 weeks, for a total of 30 minutes a day. Thoracic expansion exercises will be given to the control group as a home program for 8 weeks. All assessments will be completed in two days, before and after eight weeks of training.
Interventions
Patients in the inspiratory muscle training group will be given inspiratory muscle strength training with the Powerbreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure, 2 sets of 15 minutes a day for a total of 30 min/day or a single set of 30 min/day, 7 days/week for 8 weeks. Patients in the inspiratory muscle training group will continue their respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week. The MIPs of the patients will be re-measured every week and the training workload will be determined at 50% of the new maximal inspiratory pressure.
OTHERControl Group (breathing exercises)
Thoracic expansion exercises will be given to the control group as a home program. The control group will be asked to do thoracic expansion exercises seven days/week and 120 times/day for eight weeks. The patients in the control group will be called once a week to check their home schedules, and they will be asked to keep a diary.
Sponsors
Gazi University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Triple-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.
Intervention model description
Parallel Assignment
Eligibility
Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Between the ages of 45-80, 2. Follow-up with a diagnosis of Parkinson's disease for more than six months 3. Stages I-III according to the modified Hoehn and Yahr scale 4. Parkinson's patients with independent walking capacity will be included.
Exclusion criteria
1. Having a neurological disease other than Parkinson's disease 2. Patients with a diagnosed lung disease that may affect respiratory functions 3. At least 10 pack years or more of smoking history 4. According to the American Association of Sports Medicine (ACSM) with absolute and relative contraindications to exercise tests 5. Those with a Mini-Mental State Rating Scale score of less than 18 6. Patients with additional cardiac orthopaedic and psychological problems that limit the evaluation will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Oxygen Consumption | Trough study completion, an average of 2 year | Cardiopulmonary Exercises Test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory Muscle Strength | Trough study completion, an average of 2 year | Maximal inspiratory (MIP) and maximal expiratory (MEP) pressures expressing respiratory muscle strength were |
| Respiratory Muscle Endurance | Trough study completion, an average of 2 year | Respiratory muscle endurance will be assessed by the POWERbreathe Wellness (POWERbreathe, Inspiratory Muscle Training (IMT) Technologies Ltd., Birmingham, UK) device and the respiratory muscle endurance test at increased threshold load. |
| Pulmonary function (Forced vital capacity (FVC) | Trough study completion, an average of 2 year | Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Forced vital capacity (FVC) will be measured. |
| Pulmonary function (Forced expiratory volume in the first second (FEV1) | Trough study completion, an average of 2 year | Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Forced expiratory volume in the first second (FEV1) will be measured. |
| Pulmonary function (FEV1 / FVC) | Trough study completion, an average of 2 year | Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. FEV1 / FVC will be measured. |
| Pulmonary function (Peak flow rate (PEF)) | Trough study completion, an average of 2 year | Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Peak flow rate (PEF) will be measured. |
| Peripheral Muscle Strength | Trough study completion, an average of 2 year | Peripheral muscle strength will be evaluated with a dynamometer. |
| Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%)) | Trough study completion, an average of 2 year | Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Flow rate 25-75% of forced expiratory volume (FEF 25-75%) will be measured. |
| Upper extremity exercise capacity | Trough study completion, an average of 2 year | Upper extremity exercise capacity will be evaluated with the six-minute pegboard and ring test (6-PBRT). |
| Cough Strength | Trough study completion, an average of 2 year | Cough strength will be assessed using a peak cough flow meter (PEFmeter) (ExpiRite Peak Flow Meter, China). |
| Autonomic dysfunction | Trough study completion, an average of 2 year | It will be measured by postural change during ECG recording |
| Fatigue Severity | Trough study completion, an average of 2 year | Fatigue will be evaluated using the Parkinson Fatigue Scale. Total score varies between 16-80. As the score increases, the severity of fatigue increases. |
| Life quality | Trough study completion, an average of 2 year | Patients' health-related quality of life will be evaluated using the Parkinson's disease questionnaire-39. The total score varies between 0-156, and the quality of life worsens as the score increases. |
| Muscle oxygenation | Trough study completion, an average of 2 year | Muscle oxygenation assessment will be performed using the Moxy monitor (Moxy, Fortiori Design LLC, Minnesota, USA). |
| Physical Activity Level | Trough study completion, an average of 2 year | A multi-sensor activity monitor will be used to assess the level of physical activity. |
| Lower extremity exercise capacity | Trough study completion, an average of 2 year | Lower extremity exercise capacity will be evaluated with six- minute walking test. |
Countries
Turkey (Türkiye)
Contacts
Primary ContactMeral BOŞNAK GÜÇLÜ, Prof. Dr.
Backup ContactMusa GÜNEŞ, MsC
Outcome results
None listed